Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress

www.kamada.comSep 15 2009

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.

David Tsur, Chief Executive Officer of Kamada said, “We are delighted that Kamada was invited to present the results of its Phase II clinical study with inhaled-AAT at the European Respiratory Society meeting at a session focused on novel therapies for cystic fibrosis”. David Tsur continued, “We believe this demonstrates the excitement around our inhaled version of AAT within the field of respiratory medicine. Our product could have a significant impact on the lives of patients with cystic fibrosis and we look forward to advancing it into further clinical trials in the future”.